Kaibori Masaki, Matsushima Hideyuki, Ishizaki Morihiko, Kosaka Hisashi, Matsui Kosuke, Nakatani Miyuki, Kariya Shuji, Yamaguchi Takashi, Yoshida Katsunori, Yoshii Kengo, Sekimoto Mitsugu
Department of Surgery, Kansai Medical University, Hirakata, Japan.
Department of Radiology, Kansai Medical University, Hirakata, Japan.
Cancer Invest. 2022 Jan;40(1):81-89. doi: 10.1080/07357907.2021.1952594. Epub 2021 Aug 26.
The aim of the current study was to investigate the efficacy and safety of sorafenib and intermittent hepatic arterial infusion chemotherapy with cisplatin for unresectable hepatocellular carcinoma (HCC) with severe portal vein invasion. The antitumor effect was a complete response in 1 of 38 patients, a partial response in 12 patients, stable disease in 16 patients, and progressive disease in 9 patients, for a 34.2% response rate and a 76.3% disease control rate. This regimen had favorable efficacy and acceptable safety and may be feasible for unresectable HCC with severe portal vein invasion.
